<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id>
      <journal-id journal-id-type="publisher-id">ACN3</journal-id>
      <journal-title-group>
        <journal-title>Annals of Clinical and Translational Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2328-9503</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31353868</article-id>
      <article-id pub-id-type="pmc">6649545</article-id>
      <article-id pub-id-type="doi">10.1002/acn3.50798</article-id>
      <article-id pub-id-type="publisher-id">ACN350798</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Early second‐line therapy is associated with improved episodic memory in anti‐NMDA receptor encephalitis</article-title>
        <alt-title alt-title-type="right-running-head">Cognition in anti‐NMDA Receptor Encephalitis</alt-title>
        <alt-title alt-title-type="left-running-head">Wang <italic>et al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="acn350798-cr-0001" contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Kang</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="acn350798-note-0001">
<sup>*</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0002" contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Zhongqin</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="acn350798-note-0001">
<sup>*</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0003" contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Dengchang</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0004" contrib-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>Qiuping</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0005" contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Xuning</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0006" contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jianwen</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0007" contrib-type="author">
          <name>
            <surname>Ji</surname>
            <given-names>Caihong</given-names>
          </name>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="acn350798-cr-0008" contrib-type="author" corresp="yes">
          <name>
            <surname>Luo</surname>
            <given-names>Benyan</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9892-5778</contrib-id>
          <address>
            <email>luobenyan@zju.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="acn350798-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="acn350798-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<named-content content-type="organisation-division">The First Affiliated Hospital</named-content>
<named-content content-type="organisation-division">College of Medicine</named-content>
<institution>Zhejiang University</institution>
<named-content content-type="city">Hangzhou</named-content>
<country country="CN">China</country>
</aff>
      <aff id="acn350798-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Center for Brain Imaging Science and Technology, Key Laboratory for Biomedical engineering of Ministry of Education, College of Biomedical Engineering and Instrumental Science</named-content>
<institution>Zhejiang University</institution>
<named-content content-type="city">Hangzhou</named-content>
<country country="CN">China</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Benyan Luo, Department of Neurology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Tel: (86) 57187235101; Fax: (86)5718722 2061; E‐mail: <email>luobenyan@zju.edu.cn</email><break/></corresp>
        <fn id="acn350798-note-0001">
          <label>*</label>
          <p>These authors contributed equally to this work and should be considered co‐first authors.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>6</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>7</month>
        <year>2019</year>
      </pub-date>
      <volume>6</volume>
      <issue>7</issue>
      <issue-id pub-id-type="doi">10.1002/acn3.2019.6.issue-7</issue-id>
      <fpage>1202</fpage>
      <lpage>1213</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>2</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>4</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>5</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 American Neurological Association <copyright-statement>-->
        <copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals, Inc on behalf of American Neurological Association.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACN3-6-1202.pdf"/>
      <abstract id="acn350798-abs-0001">
        <title>Abstract</title>
        <sec id="acn350798-sec-0001">
          <title>Objective</title>
          <p>To investigate whether the early administration of intravenous second‐line immunotherapy correlates with improved long‐term cognition and the potential mechanisms via imaging in adult patients with moderate‐to‐severe anti‐N‐methyl‐D‐aspartate (NMDA) receptor encephalitis.</p>
        </sec>
        <sec id="acn350798-sec-0002">
          <title>Methods</title>
          <p>Sixteen adult patients with moderate‐to‐severe anti‐NMDA receptor encephalitis past the acute stage and 15 healthy controls (HCs) performed a set of comprehensive neuropsychological tests, and underwent a resting‐state fMRI study to analyze resting state functional connectivity (FC). In addition, correlation analyses were performed between hippocampal FC and cognitive performance. All patients were received intravenous first‐line immunotherapy, and nine of them were also given intravenous second‐line immunotherapy within 3 months of disease onset.</p>
        </sec>
        <sec id="acn350798-sec-0003">
          <title>Results</title>
          <p>The patients who only received first‐line immunotherapy showed significant verbal episodic memory impairments compared with HCs and those who received second‐line immunotherapy, while no significant differences were noted between the patients with second‐line immunotherapy and the HCs. In line with the results of neuropsychological tests, significant changes in bilateral hippocampal FC were observed in the patients who only received first‐line immunotherapy compared with both HCs and those who received second‐line immunotherapy. However, no significant differences in hippocampal FC were observed in the patients with second‐line immunotherapy compared with the HCs. Importantly, hippocampal‐medial prefrontal cortex (mPFC) connectivity positively correlated with memory performance.</p>
        </sec>
        <sec id="acn350798-sec-1000">
          <title>Interpretation</title>
          <p>In the long term, early administration of intravenous second‐line immunotherapy may be associated with more favorable verbal episodic memory outcomes in patients with moderate‐to‐severe anti‐NMDA receptor encephalitis. These results may provide some evidence and guidance for the use of immunotherapy in this population.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>Doctoral Fund of the Ministry of Education of China</funding-source>
          <award-id>20120101120070</award-id>
        </award-group>
        <award-group>
          <funding-source>National Natural Science Foundation of China</funding-source>
          <award-id>81201007</award-id>
          <award-id>81500905</award-id>
        </award-group>
        <funding-statement>This work was funded by <funding-source>Doctoral Fund of the Ministry of Education of China</funding-source> grant <award-id>20120101120070</award-id>; <funding-source>National Natural Science Foundation of China</funding-source> grants <award-id>81201007</award-id> and <award-id>81500905</award-id>. </funding-statement>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="3"/>
        <page-count count="12"/>
        <word-count count="5773"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>acn350798</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>July 2019</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.6.2 mode:remove_FC converted:23.07.2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group id="acn350798-ntgp-0001">
        <fn fn-type="funding" id="acn350798-note-0002">
          <p>
<bold>Funding information</bold>
</p>
          <p>This work was supported by grants from National Natural Science Foundation of China (81500905, 81201007) and Doctoral Fund of the Ministry of Education of China (20120101120070).</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="acn350798-sec-0004">
      <title>Introduction</title>
      <p>First characterized in 2007, anti‐N‐methyl‐D‐aspartate (anti‐NMDA) receptor encephalitis is a potentially lethal (although it is reversible with treatment), immune‐mediated brain inflammation, characterized by the acute onset of various neurological and psychiatric manifestations.<xref rid="acn350798-bib-0001" ref-type="ref">1</xref>, <xref rid="acn350798-bib-0002" ref-type="ref">2</xref>, <xref rid="acn350798-bib-0003" ref-type="ref">3</xref>, <xref rid="acn350798-bib-0004" ref-type="ref">4</xref> This disease has been recognized in patients of all ages, but is more frequent in young adults and children, with or without teratoma.<xref rid="acn350798-bib-0001" ref-type="ref">1</xref>, <xref rid="acn350798-bib-0005" ref-type="ref">5</xref> The clinical picture is similar at the end of the first month in most cases, and several symptoms are present, such as the following: abnormal behavior and cognition; memory deficit; speech disorder; seizures; abnormal movements; loss of consciousness or autonomic dysfunction; and central hypoventilation.<xref rid="acn350798-bib-0006" ref-type="ref">6</xref> Generally, timely treatments, such as first‐line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), which may be combined with second‐line immunotherapy (rituximab, cyclophosphamide), and tumour removal lead to substantial recovery, as reflected by low modified Rankin Scale (mRS) scores for approximately 80% of patients. <xref rid="acn350798-bib-0006" ref-type="ref">6</xref> However, more than 75% of patients with anti‐NMDA receptor encephalitis are left with permanent cognitive deficits of varying severity, predominantly in the domains of memory, attention, and executive control, which become major determinants of long‐term morbidity.<xref rid="acn350798-bib-0007" ref-type="ref">7</xref> Currently, only early immunotherapy is consistently considered to produce favorable cognitive outcomes.<xref rid="acn350798-bib-0007" ref-type="ref">7</xref>, <xref rid="acn350798-bib-0008" ref-type="ref">8</xref> However, studies concerning the association of second‐line immunotherapy with cognitive outcomes are limited and have shown conflicting results for anti‐NMDA receptor encephalitis.</p>
      <p>A large retrospective cohort study identified the use of second‐line immunotherapy as an additional factor for good outcomes, as reflected by low mRS scores.<xref rid="acn350798-bib-0006" ref-type="ref">6</xref> However, various cognitive function domains cannot be assessed systematically by the mRS. It is crucial to introduce comprehensive cognition evaluation tools, including a series of neuropsychological tests and functional MRI technology, to study long‐term cognitive outcomes in anti‐NMDAR encephalitis and furthermore supplement the mRS in the assessment of overall outcomes. In a recent systematic review, second‐line immunotherapy was least relevant for cognitive outcomes.<xref rid="acn350798-bib-0007" ref-type="ref">7</xref> Nevertheless, the treatment type, administration route, timing and treatment duration of second‐line therapy, disease severity, and neuropsychological tests varied significantly across the included studies.<xref rid="acn350798-bib-0007" ref-type="ref">7</xref> Therefore, conclusions from these data should be interpreted with caution. Conversely, sporadic case reports have shown that second‐line immunotherapy may improve cognitive outcomes.<xref rid="acn350798-bib-0009" ref-type="ref">9</xref> However, the cognitive outcomes in this study were based on medical history inquiries and clinical observations rather than neuropsychological assessments.</p>
      <p>The early use of second‐line immunotherapy is increasingly recommended for reducing recurrence rates; however, the choice of timing for the use of second‐line immunotherapy varies greatly among physicians. Some physicians tend to postpone second‐line immunotherapy until disease relapse instead of initiating treatment during the acute stage. Therefore, it is important to determine whether the early administration of second‐line immunotherapy is associated with long‐term cognitive outcomes improvements, which could provide insights for selecting therapeutic options in patients with moderate‐to‐severe anti‐NMDA receptor encephalitis. Therefore, 16 adult patients with moderate‐to‐severe anti‐NMDA receptor encephalitis past the acute stage were recruited in this retrospective study. All patients received intravenous first‐line immunotherapy either alone or combined with intravenous second‐line immunotherapy within 3 months after disease onset. The goal of this study was to explore whether the early administration of intravenous second‐line immunotherapy contributes to long‐term cognitive improvements and the potential underlying mechanisms by using resting functional MRI.</p>
    </sec>
    <sec sec-type="methods" id="acn350798-sec-0005">
      <title>Methods</title>
      <sec id="acn350798-sec-0006">
        <title>Subjects</title>
        <p>Sixteen patients with anti‐NMDA receptor encephalitis who were hospitalized or referred to the outpatient clinic for further counseling and treatment at the Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine were recruited between July 2016 and February 2018. The diagnosis was based on typical clinical features together with the presence of IgG antibodies for NMDA receptors.<xref rid="acn350798-bib-0002" ref-type="ref">2</xref>, <xref rid="acn350798-bib-0010" ref-type="ref">10</xref> All patients recruited in this study were considered to have moderate‐to‐severe anti‐NMDAR encephalitis, because the maximal mRS score was 4 or 5 points for all patients during the acute stage based on medical records. Assays for CSF NMDAR‐IgG, LGI1‐ IgG, CASPR2‐ IgG, AMPAR1/R2‐ IgG, and GABAB R‐IgG were performed at EUROIMMUN Diagnostic Laboratory, China by cell‐based indirect immune‐fluorescence test (IIFT) employing BIOCHIPs (EUROIMMUN AG, Luebeck, Germany). There were no abnormalities in structural MRI for any patient.</p>
        <p>All patients were evaluated using neuropsychological assessments and neuropsychiatric inventory (NPI), except for one patient who received only first‐line immunotherapy due to refusal, and all patients underwent an MRI scan. The initial assessment was conducted after the acute stage of the disease (at least 6 months after initial discharge from the hospital, median/interquartile range (IQR), 9.5/7–34.75 months; range, 6–47 months).</p>
        <p>Fifteen individuals with no history of psychiatric or neurologic disease served as healthy controls (HCs) in the experiments. The control participants were matched to the patients with respect to sex, educational level, and age. Demographic and clinical data are shown in Tables <xref rid="acn350798-tbl-0001" ref-type="table">1</xref> and <xref rid="acn350798-tbl-0002" ref-type="table">2</xref>.</p>
        <table-wrap id="acn350798-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Patient characteristics.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" rowspan="2" valign="top" colspan="1">Patient</th>
                <th align="left" rowspan="2" valign="top" colspan="1">Sex</th>
                <th align="left" rowspan="2" valign="top" colspan="1">Age</th>
                <th align="left" rowspan="2" valign="top" colspan="1">IgGNMDA receptor antibodies (CSF titer)</th>
                <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Symptoms</th>
                <th align="left" rowspan="2" valign="top" colspan="1">Duration of unconsciousness, day</th>
                <th align="left" rowspan="2" valign="top" colspan="1">Treatment protocol</th>
                <th align="left" rowspan="2" valign="top" colspan="1">Hospital stay month</th>
                <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Paraneoplastic syndrome</th>
                <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">mRS score</th>
                <th align="left" rowspan="2" valign="top" colspan="1">AEDs at study time point</th>
              </tr>
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Initial</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Total</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Tumor</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Resection</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Before treatment</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Study time point</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">22</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, seizure</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">15–20</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.1</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">Topiramate 50 mg/day</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">2</td>
                <td align="left" rowspan="1" colspan="1">M</td>
                <td align="left" rowspan="1" colspan="1">28</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, dyskinesia</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td>
                <td align="left" rowspan="1" colspan="1">20–25</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">3</td>
                <td align="left" rowspan="1" colspan="1">M</td>
                <td align="left" rowspan="1" colspan="1">31</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Seizure, LOC</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition, autonomic instability</td>
                <td align="left" rowspan="1" colspan="1">25–30</td>
                <td align="left" rowspan="1" colspan="1">IVIG, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.4</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">15</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Dyskinesia, seizure</td>
                <td align="left" rowspan="1" colspan="1">Dyskinesia, seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">Oxcarbazepine 900 mg/day</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">24</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">10–15</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">6</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">34</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition, autonomic instability</td>
                <td align="left" rowspan="1" colspan="1">700+</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, plasmapheresis, IVIG, rituximab, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">26</td>
                <td align="left" rowspan="1" colspan="1">Mature cystic teratoma of left ovarian</td>
                <td align="left" rowspan="1" colspan="1">yes</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">7</td>
                <td align="left" rowspan="1" colspan="1">M</td>
                <td align="left" rowspan="1" colspan="1">22</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">10–15</td>
                <td align="left" rowspan="1" colspan="1">Cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">0.8</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">8</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">25</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, seizure</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">20–25</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">Mature cystic teratoma of bilateral ovarian</td>
                <td align="left" rowspan="1" colspan="1">yes</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">9</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">20</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, dyskinesia</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizures, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">20–25</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG, rituximab, cyclophosphamide</td>
                <td align="left" rowspan="1" colspan="1">1.3</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">10</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">30</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior</td>
                <td align="left" rowspan="1" colspan="1">LOC, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">8–10</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">0.7</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">11</td>
                <td align="left" rowspan="1" colspan="1">M</td>
                <td align="left" rowspan="1" colspan="1">49</td>
                <td align="left" rowspan="1" colspan="1">1:10</td>
                <td align="left" rowspan="1" colspan="1">Seizure, behavior</td>
                <td align="left" rowspan="1" colspan="1">LOC, dyskinesia, seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">15–20</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">12</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">34</td>
                <td align="left" rowspan="1" colspan="1">1:10</td>
                <td align="left" rowspan="1" colspan="1">Dyskinesia, cognition</td>
                <td align="left" rowspan="1" colspan="1">Dyskinesia, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">0.8</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">13</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">42</td>
                <td align="left" rowspan="1" colspan="1">1:10</td>
                <td align="left" rowspan="1" colspan="1">Seizure, behavior,</td>
                <td align="left" rowspan="1" colspan="1">LOC, seizure, behavior, cognition, autonomic instability</td>
                <td align="left" rowspan="1" colspan="1">20–25</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">25</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Seizure, behavior,</td>
                <td align="left" rowspan="1" colspan="1">Seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">1.3</td>
                <td align="left" rowspan="1" colspan="1">Mature cystic teratoma of right ovarian</td>
                <td align="left" rowspan="1" colspan="1">yes</td>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">15</td>
                <td align="left" rowspan="1" colspan="1">M</td>
                <td align="left" rowspan="1" colspan="1">22</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, seizure</td>
                <td align="left" rowspan="1" colspan="1">LOC, seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">20–25</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">1.3</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">0</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">16</td>
                <td align="left" rowspan="1" colspan="1">F</td>
                <td align="left" rowspan="1" colspan="1">52</td>
                <td align="left" rowspan="1" colspan="1">1:32</td>
                <td align="left" rowspan="1" colspan="1">Behavior, seizure</td>
                <td align="left" rowspan="1" colspan="1">Seizure, behavior, cognition</td>
                <td align="left" rowspan="1" colspan="1">NA</td>
                <td align="left" rowspan="1" colspan="1">High‐dose steroids, IVIG</td>
                <td align="left" rowspan="1" colspan="1">1.2</td>
                <td align="left" rowspan="1" colspan="1">None</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">None</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="acn350798-note-0003">
              <p>CSF, cerebrospinal fluid; LOC, loss of consciousness; IVIG, intravenous human immunoglobulin; mRS, modified Rankin Score; AEDs, antiepileptic drugs; NA, not applicable.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <table-wrap id="acn350798-tbl-0002" xml:lang="en" orientation="portrait" position="float">
          <label>Table 2</label>
          <caption>
            <p>Demographic data and various putative predictive factors of the patients and healthy controls.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Clinical variables</th>
                <th align="left" valign="top" rowspan="1" colspan="1">HC</th>
                <th align="left" valign="top" rowspan="1" colspan="1">First‐line only</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Second‐line</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<italic>F</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0005">a</xref>
</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<italic>χ</italic>
<sup>2</sup> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0006">b</xref>
</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<italic>t</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0007">c</xref>
</th>
                <th align="left" valign="top" rowspan="1" colspan="1">
<italic>U</italic> (<italic>P</italic>)<xref ref-type="fn" rid="acn350798-note-0008">d</xref>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Age (X ± SD, year)</td>
                <td align="left" rowspan="1" colspan="1">30.27 ± 7.70</td>
                <td align="left" rowspan="1" colspan="1">34.43 ± 10.85</td>
                <td align="left" rowspan="1" colspan="1">25.33 ± 4.82</td>
                <td align="left" rowspan="1" colspan="1">2.7 (0.084)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Education (X ± SD, year)</td>
                <td align="left" rowspan="1" colspan="1">14.13 ± 2.07</td>
                <td align="left" rowspan="1" colspan="1">11.14 ± 4.26</td>
                <td align="left" rowspan="1" colspan="1">12.78 ± 3.63</td>
                <td align="left" rowspan="1" colspan="1">2.23 (0.126)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Sex (Male/Female)</td>
                <td align="left" rowspan="1" colspan="1">5/10</td>
                <td align="left" rowspan="1" colspan="1">2/5</td>
                <td align="left" rowspan="1" colspan="1">3/6</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">0.056 (0.97)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">EEG abnormality (Absent/Present)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">2/5</td>
                <td align="left" rowspan="1" colspan="1">3/6</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">0.042 (0.838)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Seizures (Absent/Present)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">2/5</td>
                <td align="left" rowspan="1" colspan="1">0/9</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">2.94 (0.086)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">ICU treatment (Absent/Present)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">7/0</td>
                <td align="left" rowspan="1" colspan="1">8/1</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">0.83 (0.362)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Etiology (Idiopathic/Paraneoplastic)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">6/1</td>
                <td align="left" rowspan="1" colspan="1">7/2</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">0.163 (0.687)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Time of definite diagnosis (X ± SD, day)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">18.57 ± 7.61</td>
                <td align="left" rowspan="1" colspan="1">16.89 ± 9.13</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">‐0.39 (0.70)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Time of follow‐up after initial discharge (median/IQR; range, month)</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">31/7–38; 6–47</td>
                <td align="left" rowspan="1" colspan="1">9/6.5–11.5; 6–44</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">/</td>
                <td align="left" rowspan="1" colspan="1">18.50 (0.167)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="acn350798-note-0004">
              <p>EDB, extreme delta brush; IQR, interquartile range; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy;</p>
            </fn>
            <fn id="acn350798-note-0005">
              <label>a</label>
              <p>one‐way analysis of variance (ANOVA);</p>
            </fn>
            <fn id="acn350798-note-0006">
              <label>b</label>
              <p>Chi‐square test;</p>
            </fn>
            <fn id="acn350798-note-0007">
              <label>c</label>
              <p>Two‐sample <italic>t</italic>‐test;</p>
            </fn>
            <fn id="acn350798-note-0008">
              <label>d</label>
              <p>Mann–Whitney <italic>U</italic> test.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>All subjects provided written informed consent, and the project was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.</p>
      </sec>
    </sec>
    <sec id="acn350798-sec-0007">
      <title>Treatment protocol</title>
      <p>In the current study, the first‐line immunotherapy protocol at our institute was defined as high‐dose steroids (500–1000 mg of methylprednisolone daily for 3 days, followed by tapering) and intravenous immunoglobulin (IVIG) (0.4 g/kg for 5 days) with or without plasmapheresis (before IVIG, once), and second‐line immunotherapy was defined as intravenous rituximab (375 mg/m<sup>2</sup> weekly for 4 weeks) and cyclophosphamide (750 mg/m<sup>2</sup> monthly for 4–6 months, depending on the response), in combination or alone.</p>
      <p>All patients received first‐line immunotherapy at 1–3 days after a definite diagnosis; nine of them also received second‐line immunotherapy at 7–56 days after first‐line immunotherapy. Treatment administered within 3 months of disease onset was considered early immunotherapy. The therapeutic strategy was selected at the treating clinicians’ discretion. Some physicians are more proactive and choose to apply second‐line immunotherapy at the acute stage when a patient’s condition is sufficiently severe, while others tend to postpone immunotherapy until disease relapse.</p>
    </sec>
    <sec id="acn350798-sec-0008">
      <title>Neuropsychological assessment</title>
      <p>A set of comprehensive neuropsychological tests was administered to assess working memory (digit span test) and verbal episodic memory (Chinese auditory verbal learning test, CAVLT), as well as the Stroop test, semantic fluency test, block design test, symbol‐digit modalities test (SDMT), self‐rating anxiety scale (SAS), and self‐rating depression scale (SDS).</p>
    </sec>
    <sec id="acn350798-sec-0009">
      <title>Resting‐state functional connectivity analysis</title>
      <p>Acquisition and initial image preprocessing of resting‐state fMRI data are provided in detail in the Data <xref rid="acn350798-sup-0001" ref-type="supplementary-material">S1</xref>. The left and right hippocampal seed regions were extracted from the Anatomical Automatic Labeling (AAL) template. The Pearson correlation coefficient between the mean time courses of each seed region and those of each voxel throughout the whole brain was calculated for each individual.<xref rid="acn350798-bib-0011" ref-type="ref">11</xref> The resulting correlation coefficients were transformed into <italic>z</italic>‐values using Fisher’s transformation.</p>
      <sec id="acn350798-sec-0010">
        <title>Statistical analysis</title>
        <p>Statistical analyses were performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL). A Chi‐square test was used for categorical variables, and demographic variables were compared between groups using a one‐way analysis of variance (ANOVA), two‐sample <italic>T</italic>‐test, or Mann–Whitney <italic>U</italic> test.</p>
        <p>One‐way ANOVA was used to compare the FC between the left and right hippocampus among the three groups within a whole‐brain mask (FA &gt; 0.2) using the DPABI toolbox. The main effect F‐maps were set at a significance threshold of <italic>P</italic> &lt; 0.001 (Gaussian Random Field theory correction (GRF) was used for multiple comparisons). Post hoc comparisons were performed in local clusters with significant group differences to compare the three groups. To estimate the relationship between FC and neuropsychological test results in all participants, we calculated the Pearson correlations between each neuropsychological tests score and the FC value of the left or right hippocampus in local clusters with significant group differences. The correlations were considered significant at a threshold of <italic>P</italic> &lt; 0.05.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="acn350798-sec-0011">
      <title>Results</title>
      <sec id="acn350798-sec-0012">
        <title>Demographic and clinical data</title>
        <p>The patients who received only first‐line therapy, the patients who received second‐line immunotherapy and the HCs did not differ significantly with regard to age (<italic>F</italic> = 2.84, <italic>P</italic> = 0.08), educational level (<italic>F</italic> = 1.70, <italic>P</italic> = 0.20) or sex (<italic>χ</italic>
<sup>2</sup> = 0.64, <italic>P</italic> = 0.73) (Table <xref rid="acn350798-tbl-0002" ref-type="table">2</xref>). In addition, all patients (11 women; mean age, 28.81 ± 9.86 years; education, 12.38 ± 3.34 years) and HCs did not differ significantly regarding age (<italic>t</italic> = 0.98, <italic>P</italic> = 0.34), educational level (<italic>t</italic> = 1.51, <italic>P</italic> = 0.14), or sex (<italic>χ</italic>
<sup>2</sup> = 0.015, <italic>P</italic> = 0.90). With regard to time of definite diagnosis, the patients with first‐line immunotherapy only and those with second‐line immunotherapy did not show a significant difference (<italic>t</italic> = −0.39, <italic>P</italic> = 0.70) (Table <xref rid="acn350798-tbl-0002" ref-type="table">2</xref>). According to the Mann–Whitney <italic>U</italic> test, the patients with first‐line immunotherapy only and those with second‐line immunotherapy did not show a significant difference (<italic>U</italic> = 18.50, <italic>P</italic> = 0.167) with regard to time of follow‐up after initial discharge (Table <xref rid="acn350798-tbl-0002" ref-type="table">2</xref>). In addition, the patients with second‐line immunotherapy and those with first‐line immunotherapy only did not differ significantly with regard to mRS scores (<italic>t</italic> = 1.43, <italic>P</italic> = 0.17) or potential predictive factors (EDB, <italic>χ</italic>
<sup>2</sup> = 0.04, <italic>P</italic> = 0.84; seizures, <italic>χ</italic>
<sup>2</sup> = 2.94, <italic>P</italic> = 0.09; ICU treatment, <italic>χ</italic>
<sup>2</sup> = 0.83, <italic>P</italic> = 0.36; etiology, <italic>χ</italic>
<sup>2</sup> = 0.16, <italic>P</italic> = 0.69). The demographic and clinical data are shown in Tables <xref rid="acn350798-tbl-0001" ref-type="table">1</xref> and <xref rid="acn350798-tbl-0002" ref-type="table">2</xref>.</p>
      </sec>
    </sec>
    <sec id="acn350798-sec-0013">
      <title>Neuropsychological assessment</title>
      <p>No patients had any psychotic symptoms according NPI. The neuropsychological test results assessed by one‐way ANOVA are shown in Table <xref rid="acn350798-tbl-0003" ref-type="table">3</xref>. The patients showed significant impairments in the SDMT (<italic>F</italic> = 11.25, <italic>P</italic> = 0.000), digit span test (forward, <italic>F</italic> = 4.17, <italic>P</italic> = 0.026; backward, <italic>F</italic> = 6.93, <italic>P</italic> = 0.004), semantic fluency test (<italic>F</italic> = 4.34, <italic>P</italic> = 0.023), block design test (<italic>F</italic> = 4.61, <italic>P</italic> = 0.019), and CAVLT (immediate memory following interference, <italic>F</italic> = 8.49, <italic>P</italic> = 0.001; delayed recall, <italic>F</italic> = 5.23, <italic>P</italic> = 0.012; recognition, <italic>F</italic> = 4.65, <italic>P</italic> = 0.034), whereas scores of the Stroop test (<italic>F</italic> = 1.81, <italic>P</italic> = 0.183), self‐rating anxiety scale (<italic>F</italic> = 0.76, <italic>P</italic> = 0.493) and self‐rating depression scale (<italic>F</italic> = 0.85, <italic>P</italic> = 0.456) were normal.</p>
      <table-wrap id="acn350798-tbl-0003" xml:lang="en" orientation="portrait" position="float">
        <label>Table 3</label>
        <caption>
          <p>Summary of the neuropsychological test results among the patients and healthy controls.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <thead valign="top">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" rowspan="2" valign="top" colspan="1">Tests</th>
              <th align="left" rowspan="2" valign="top" colspan="1">HC</th>
              <th align="left" rowspan="2" valign="top" colspan="1">Second‐line</th>
              <th align="left" rowspan="2" valign="top" colspan="1">First‐line only</th>
              <th align="left" rowspan="2" valign="top" colspan="1">
<italic>F</italic>
</th>
              <th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic>
</th>
              <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Post hoc analysis (<italic>P</italic>)</th>
            </tr>
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="top" rowspan="1" colspan="1">HC vs. second‐line</th>
              <th align="left" valign="top" rowspan="1" colspan="1">HC vs. first‐line only</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Second‐line vs. first‐line only</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Stroop test (dot)</td>
              <td align="left" rowspan="1" colspan="1">12.94 ± 2.64</td>
              <td align="left" rowspan="1" colspan="1">14.05 ± 2.62</td>
              <td align="left" rowspan="1" colspan="1">15.24 ± 2.36</td>
              <td align="left" rowspan="1" colspan="1">1.81</td>
              <td align="left" rowspan="1" colspan="1">0.183</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Stroop test (color word)</td>
              <td align="left" rowspan="1" colspan="1">24.04 ± 4.80</td>
              <td align="left" rowspan="1" colspan="1">30.91 ± 10.41</td>
              <td align="left" rowspan="1" colspan="1">37.89 ± 16.36</td>
              <td align="left" rowspan="1" colspan="1">3.35</td>
              <td align="left" rowspan="1" colspan="1">0.080</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SDMT</td>
              <td align="left" rowspan="1" colspan="1">62.87 ± 7.80</td>
              <td align="left" rowspan="1" colspan="1">48.78 ± 8.97</td>
              <td align="left" rowspan="1" colspan="1">43.83 ± 13.66</td>
              <td align="left" rowspan="1" colspan="1">11.25</td>
              <td align="left" rowspan="1" colspan="1">0.000</td>
              <td align="left" rowspan="1" colspan="1">0.002</td>
              <td align="left" rowspan="1" colspan="1">0.000</td>
              <td align="left" rowspan="1" colspan="1">0.331</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Digit span test (forward)</td>
              <td align="left" rowspan="1" colspan="1">9.40 ± 1.12</td>
              <td align="left" rowspan="1" colspan="1">8.00 ± 1.32</td>
              <td align="left" rowspan="1" colspan="1">8.00 ± 1.78</td>
              <td align="left" rowspan="1" colspan="1">4.17</td>
              <td align="left" rowspan="1" colspan="1">0.026</td>
              <td align="left" rowspan="1" colspan="1">0.019</td>
              <td align="left" rowspan="1" colspan="1">0.038</td>
              <td align="left" rowspan="1" colspan="1">1.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Digit span test (backward)</td>
              <td align="left" rowspan="1" colspan="1">7.53 ± 1.46</td>
              <td align="left" rowspan="1" colspan="1">5.33 ± 1.00</td>
              <td align="left" rowspan="1" colspan="1">6.00 ± 2.00</td>
              <td align="left" rowspan="1" colspan="1">6.93</td>
              <td align="left" rowspan="1" colspan="1">0.004</td>
              <td align="left" rowspan="1" colspan="1">0.001</td>
              <td align="left" rowspan="1" colspan="1">0.039</td>
              <td align="left" rowspan="1" colspan="1">0.395</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Semantic Fluency Test</td>
              <td align="left" rowspan="1" colspan="1">21.87 ± 5.15</td>
              <td align="left" rowspan="1" colspan="1">19.44 ± 4.77</td>
              <td align="left" rowspan="1" colspan="1">15.33 ± 2.07</td>
              <td align="left" rowspan="1" colspan="1">4.34</td>
              <td align="left" rowspan="1" colspan="1">0.023</td>
              <td align="left" rowspan="1" colspan="1">0.224</td>
              <td align="left" rowspan="1" colspan="1">0.007</td>
              <td align="left" rowspan="1" colspan="1">0.103</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Block Design Test</td>
              <td align="left" rowspan="1" colspan="1">40.60 ± 6.63</td>
              <td align="left" rowspan="1" colspan="1">32.22 ± 6.57</td>
              <td align="left" rowspan="1" colspan="1">31.67 ± 11.55</td>
              <td align="left" rowspan="1" colspan="1">4.61</td>
              <td align="left" rowspan="1" colspan="1">0.019</td>
              <td align="left" rowspan="1" colspan="1">0.016</td>
              <td align="left" rowspan="1" colspan="1">0.025</td>
              <td align="left" rowspan="1" colspan="1">0.893</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CAVLT (immediate memory following interference)</td>
              <td align="left" rowspan="1" colspan="1">13.73 ± 1.10</td>
              <td align="left" rowspan="1" colspan="1">13.56 ± 1.23</td>
              <td align="left" rowspan="1" colspan="1">11.17 ± 1.94</td>
              <td align="left" rowspan="1" colspan="1">8.49</td>
              <td align="left" rowspan="1" colspan="1">0.001</td>
              <td align="left" rowspan="1" colspan="1">0.754</td>
              <td align="left" rowspan="1" colspan="1">0.000</td>
              <td align="left" rowspan="1" colspan="1">0.002</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CAVLT (delayed recall)</td>
              <td align="left" rowspan="1" colspan="1">13.27 ± 1.71</td>
              <td align="left" rowspan="1" colspan="1">12.78 ± 1.72</td>
              <td align="left" rowspan="1" colspan="1">10.67 ± 1.51</td>
              <td align="left" rowspan="1" colspan="1">5.23</td>
              <td align="left" rowspan="1" colspan="1">0.012</td>
              <td align="left" rowspan="1" colspan="1">0.495</td>
              <td align="left" rowspan="1" colspan="1">0.003</td>
              <td align="left" rowspan="1" colspan="1">0.024</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CAVLT (recognition)</td>
              <td align="left" rowspan="1" colspan="1">14.80 ± 0.41</td>
              <td align="left" rowspan="1" colspan="1">14.89 ± 0.33</td>
              <td align="left" rowspan="1" colspan="1">13.50 ± 1.05</td>
              <td align="left" rowspan="1" colspan="1">4.65</td>
              <td align="left" rowspan="1" colspan="1">0.034</td>
              <td align="left" rowspan="1" colspan="1">0.834</td>
              <td align="left" rowspan="1" colspan="1">0.062</td>
              <td align="left" rowspan="1" colspan="1">0.049</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Self‐rating anxiety scale</td>
              <td align="left" rowspan="1" colspan="1">23.47 ± 3.04</td>
              <td align="left" rowspan="1" colspan="1">25.11 ± 6.43</td>
              <td align="left" rowspan="1" colspan="1">26.33 ± 5.96</td>
              <td align="left" rowspan="1" colspan="1">0.76</td>
              <td align="left" rowspan="1" colspan="1">0.493</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Self‐rating depression scale</td>
              <td align="left" rowspan="1" colspan="1">23.53 ± 3.83</td>
              <td align="left" rowspan="1" colspan="1">26.89 ± 7.66</td>
              <td align="left" rowspan="1" colspan="1">25.33 ± 5.68</td>
              <td align="left" rowspan="1" colspan="1">0.85</td>
              <td align="left" rowspan="1" colspan="1">0.456</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
              <td align="left" rowspan="1" colspan="1">/</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="acn350798-note-0009">
            <p>SDMT, symbol‐digit modalities test; CAVLT, Chinese auditory verbal learning test; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.</p>
          </fn>
        </table-wrap-foot>
        <permissions>
          <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
        </permissions>
      </table-wrap>
      <p>Post hoc comparisons (least‐significant difference correction, LSD) showed that CAVLT did not differ significantly between the HCs and the patients with second‐line immunotherapy (immediate memory following interference, <italic>P</italic> = 0.754; delayed recall, <italic>P</italic> = 0.459; recognition, <italic>P</italic> = 0.843). However, the patients who received only first‐line immunotherapy showed significant verbal episodic memory impairments compared with both those who received second‐line immunotherapy (immediate memory following interference, <italic>P</italic> = 0.002; delayed recall, <italic>P</italic> = 0.024; recognition, <italic>P</italic> = 0.049) and HCs (immediate memory following interference, <italic>P</italic> = 0.000; delayed recall, <italic>P</italic> = 0.003). To consider whether time of follow‐up had an impact on verbal episodic memory improvements, we compared the memory performance between the patients with only 6–12 months of follow‐up and those with more than 1 year of follow‐up. The results showed that there were no significant differences regarding memory performance.</p>
      <p>In addition, compared with the HCs, the patients with first‐line only and those with second‐line immunotherapy showed significant impairments in the following tests: the SDMT (HCs vs. first‐line only, <italic>P</italic> = 0.000; HCs vs. second‐line therapy, <italic>P</italic> = 0.002), digit span test (HCs vs. first‐line only, <italic>P</italic> = 0.038; HCs vs. second‐line therapy, <italic>P</italic> = 0.019), and block design test (HCs vs. first‐line only, <italic>P</italic> = 0.039; HCs vs. second‐line therapy, <italic>P</italic> = 0.001). Only the patients who received only first‐line immunotherapy showed significant impairments in the semantic fluency test (HCs vs. first‐line only, <italic>P</italic> = 0.007). However, no differences were observed between the patients with first‐line only and those with second‐line immunotherapy in the above tests.</p>
    </sec>
    <sec id="acn350798-sec-0014">
      <title>Resting‐state FC</title>
      <p>Voxel‐wise analysis of left hippocampal functional connectivity (FC) showed decreased FC in the left hippocampus with the medial prefrontal cortex (mPFC), and increased FC in the left hippocampus with the bilateral sensorimotor cortices (SMC) and supplementary motor area (SMA) (<italic>P</italic> &lt; 0.001, GRF‐corrected, cluster size &gt; 30; Fig. <xref rid="acn350798-fig-0001" ref-type="fig">1</xref>). A post hoc analysis demonstrated that the patients who received only first‐line immunotherapy showed a significant reduction in left hippocampal FC with the mPFC and significant increases in left hippocampal FC with the bilateral SMC and SMA compared with both the HCs and those who received second‐line immunotherapy (Fig. <xref rid="acn350798-fig-0001" ref-type="fig">1</xref>). No significant differences in left hippocampal FC were noted in the patients with second‐line immunotherapy compared with the HCs (Fig. <xref rid="acn350798-fig-0001" ref-type="fig">1</xref>).</p>
      <fig fig-type="Figure" xml:lang="en" id="acn350798-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Significant resting‐state functional connectivity changes between the left hippocampus and cerebral cortex in patients with anti‐NMDA receptor encephalitis. Hip, hippocampus; L, left; R, right; mPFC, medial prefrontal cortex; SMC, sensorimotor cortex; SMA, supplementary motor area; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="ACN3-6-1202-g001"/>
      </fig>
      <p>Similarly, voxel‐wise analysis of right hippocampal FC showed significant reductions in the right hippocampal FC with the mPFC, inferior‐parietal lobule (IPL), and bilateral dorsolateral prefrontal cortex (DLPFC), while significant increases were observed in right hippocampal FC with the bilateral SMC (<italic>P</italic> &lt; 0.001, GRF‐corrected, cluster size &gt; 30; Fig. <xref rid="acn350798-fig-0002" ref-type="fig">2</xref>). A post hoc analysis demonstrated that the patients who received only first‐line immunotherapy showed significant reductions in right hippocampal FC with the mPFC, IPL and bilateral DLPFC and significant increases in right hippocampal FC with the bilateral SMC compared with that in both the HCs and patients with second‐line immunotherapy (Fig. <xref rid="acn350798-fig-0002" ref-type="fig">2</xref>). No significant differences were noted in right hippocampal FC in the patients with second‐line immunotherapy compared with the HCs (Fig. <xref rid="acn350798-fig-0002" ref-type="fig">2</xref>).</p>
      <fig fig-type="Figure" xml:lang="en" id="acn350798-fig-0002" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Significant resting‐state functional connectivity changes between the right hippocampus and cerebral cortex in patients with anti‐NMDA receptor encephalitis. Hip, hippocampus; L, left; R, right; mPFC, medial prefrontal cortex; SMC, sensorimotor cortex; SMA, supplementary motor area; DLPFC, dorsolateral prefrontal cortex; IPL, inferior‐parietal lobule; HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="ACN3-6-1202-g002"/>
      </fig>
      <p>A linear correlation analysis showed a significant positive correlation between bilateral hippocampal‐mPFC FC and CAVLT‐interference memory performance (left hippocampus, <italic>r</italic> = 0.453, <italic>P</italic> = 0.012; right hippocampus, <italic>r</italic> = 0.363, <italic>P</italic> = 0.04) and between right hippocampal‐RIPL FC and CAVLT‐interference memory performance (<italic>r</italic> = 0.41, <italic>P</italic> = 0.025) (Fig. <xref rid="acn350798-fig-0003" ref-type="fig">3</xref>). In addition, significant negative correlations were found between left hippocampal‐bilateral SMC FC and CAVLT‐Interference memory performance (left SMC, <italic>r</italic> = −0.57, <italic>P</italic> &lt; 0.001; right SMC, <italic>r</italic> = −0.49, <italic>P</italic> = 0.0057) and between left hippocampal‐LSMC FC and CAVLT‐delayed memory performance (<italic>r</italic> = −0.53, <italic>P</italic> = 0.0026) (Fig. <xref rid="acn350798-fig-0003" ref-type="fig">3</xref>). No significant correlations between hippocampal‐mPFC FC and performance in the tests of working memory, semantic fluency, or block design were observed.</p>
      <fig fig-type="Figure" xml:lang="en" id="acn350798-fig-0003" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Significant correlations between hippocampal functional connectivity and individual episodic memory performance in patients with anti‐NMDA receptor encephalitis. Hip, hippocampus; L, left; R, right; mPFC, medial prefrontal cortex; SMC, sensorimotor cortex; IPL, inferior‐parietal lobule; CAVLT‐interference, Chinese auditory verbal learning test (immediate memory following interference); CAVLT‐delayed, Chinese auditory verbal learning test (delayed recall); HC, healthy control group; first‐line only, the patients who received only first‐line immunotherapy; second‐line, the patients who received first‐line and second‐line immunotherapy.</p>
        </caption>
        <graphic id="nlm-graphic-5" xlink:href="ACN3-6-1202-g003"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="acn350798-sec-0015">
      <title>Discussion</title>
      <p>Our study demonstrated that all patients received early immunotherapy and achieved good outcome (mRS, 0–2); however, in terms of verbal episodic memory, the patients who only received with first‐line immunotherapy showed significant impairments compared with both those who received second‐line immunotherapy and HCs, while no significant differences were noted in the patients with second‐line immunotherapy compared with the HCs. These results were consistent with that of a previous study<xref rid="acn350798-bib-0006" ref-type="ref">6</xref> but extended the findings to indicate that the early administration of intravenous second‐line immunotherapy may be associated with improved long‐term verbal episodic memory in patients with moderate‐to‐severe anti‐NMDA receptor encephalitis. However, other domains of cognition (SDMT, digit span test and block design test), which reflected frontal‐parietal function, did not return to normal levels in the patients with second‐line immunotherapy. This finding indicated that cognitive impairments of varying degrees may persist for a long time in critically ill patients despite aggressive treatment.</p>
      <p>The clinical picture of the patients was typical, and a definite diagnosis of the patients was relatively timely in our study. Both first‐line and second‐line immunotherapy were applied in the early stage of the disease. The types, medication dosage, route of administration, and duration of immunotherapy were similar. There was no significant difference between the patients with first‐line immunotherapy only and those with second‐line immunotherapy with regard to the time of definite diagnosis, time of first‐line immunotherapy administration, potential predictive factors (EDB, seizures, ICU treatment and etiology), or time of follow‐up. Therefore, we believe that the verbal episodic memory improvements were not related to these factors.</p>
      <p>The results of neuropsychological tests are not consistent with a previous study reporting that second‐line immunotherapy was less relevant to cognitive outcomes involving episodic memory.<xref rid="acn350798-bib-0007" ref-type="ref">7</xref> There are a number of confounding factors that may account for this discrepancy.<xref rid="acn350798-bib-0006" ref-type="ref">6</xref> Firstly, patients treated with second‐line immunotherapy were of greater severity than those who received only first‐line immunotherapy in the reported studies. In our study, we only included patients with moderate‐to‐severe anti‐NMDAR encephalitis. Secondly, patients in our study received intravenous second‐line immunosuppressants within 3 months of disease onset, whereas the timing varies in the literature. In most cases, second‐line immunotherapy was not initiated until first‐line therapy failed, which usually occurred at a relatively advanced stage.<xref rid="acn350798-bib-0006" ref-type="ref">6</xref> Other factors, such as the medication dosage, route of administration, duration of second‐line therapy, severity of the disease, and neuropsychological tests, may also influence cognitive performance.</p>
      <p>Previous studies have reported that memory appears to be the most affected domain among all cognitive dysfunctions and was reported to highly correlate with an increased density of NMDA receptors in the hippocampus.<xref rid="acn350798-bib-0012" ref-type="ref">12</xref> Functional MRI studies have also demonstrated that reduced hippocampal FC,<xref rid="acn350798-bib-0012" ref-type="ref">12</xref>, <xref rid="acn350798-bib-0013" ref-type="ref">13</xref> hippocampal volumetrics, and microstructural integrity<xref rid="acn350798-bib-0014" ref-type="ref">14</xref> are associated with individual memory performance in patients with anti‐NMDA receptor encephalitis. In consistent with previous observations,<xref rid="acn350798-bib-0012" ref-type="ref">12</xref>, <xref rid="acn350798-bib-0013" ref-type="ref">13</xref> our study observed hippocampal FC with the mPFC decreased significantly and correlated with impaired memory performance in patients who received only first‐line immunotherapy. This finding was supported by the neuropsychological results that early intravenous second‐line immunotherapy may be associated with verbal episodic memory improvements.</p>
      <p>Notably, a reduction in right hippocampal FC with the posterior DMN (IPL), but not the anterior DMN, was first observed in patients with anti‐NMDA receptor encephalitis.<xref rid="acn350798-bib-0012" ref-type="ref">12</xref>, <xref rid="acn350798-bib-0013" ref-type="ref">13</xref> Numerous studies support the notion that the IPL is part of the DMN and plays an important role in episodic memory.<xref rid="acn350798-bib-0015" ref-type="ref">15</xref> Normal anatomy and FC between the hippocampus and IPL are critically important for episodic memory processing.<xref rid="acn350798-bib-0016" ref-type="ref">16</xref> Therefore, reduced right hippocampal FC with the IPL may serve as a biomarker for anti‐NMDA receptor encephalitis and may be a primary factor in the episodic memory impairment associated with the disease.</p>
      <p>Aside from the DMN, a reduction in right hippocampal FC with the bilateral DLPFC, as well as increases in bilateral hippocampal FC with the bilateral SMC and in left hippocampal FC with the SMA, were observed in the patients who received only first‐line immunotherapy. We also found that the alternations in left hippocampal FC with the bilateral SMC negatively correlated with memory performance. The hypothesis that the anterior DLPFC may be instrumental in implementing a top‐down inhibitory control signal that suppresses mnemonic processing has been supported in several studies.<xref rid="acn350798-bib-0017" ref-type="ref">17</xref> Moreover, increasing evidence supports SMC dysfunction in Alzheimer’s disease (AD),<xref rid="acn350798-bib-0018" ref-type="ref">18</xref> and decreased or rewired sensorimotor network connectivity in AD has been reported, even at an early stage, <xref rid="acn350798-bib-0019" ref-type="ref">19</xref>, <xref rid="acn350798-bib-0020" ref-type="ref">20</xref> indicating that SMC connectivity may be associated with episodic memory processing. This contrary relationship between increased alternations in bilateral hippocampal FC with the SMC and reduced bilateral hippocampal FC with the DMN in the patients who received only first‐line immunotherapy may reflect an intrinsically inversely correlated relationship between the task‐negative DMN and task‐positive sensorimotor networks.<xref rid="acn350798-bib-0021" ref-type="ref">21</xref>
</p>
      <p>This study had limitations that should be considered in interpreting our results. First, the study used a retrospective design rather than a prospective design. Hence, selection bias with treatment and bias related to time of treatment could not be avoided. A second limitation is the small sample size. Third, although all patients achieved a good overall outcome (mRS, 0–2), and there were no significant differences regarding memory performance between the patients with only 6–12 months of follow‐up and those with more than 1 year of follow‐up, the challenge regarding follow‐up variability should be noted. Fourth, because this study focused on patients with moderate‐to‐severe anti‐NMDAR encephalitis, it remains unclear whether the same association will apply to cognitive function in mild cases. Additional larger, longitudinal studies from different centers and multimodal functional MRI examinations are needed to determine the association between second‐line immunotherapy and cognitive function improvements.</p>
      <p>In summary, the present study suggests that in the long term, the early administration of second‐line immunotherapy in patients with moderate‐to‐severe anti‐NMDA receptor encephalitis may be associated with more favorable overall verbal episodic memory outcomes. Early intervention with aggressive immunosuppressants may be justifiable in this population.</p>
    </sec>
    <sec id="acn350798-sec-0017">
      <title>Author Contributions</title>
      <p>Study concept and design: K. Wang, Z. Q. Chen and B. Y. Luo; data acquisition, analysis and interpretation: all authors; drafting of the manuscript: K. Wang and Z. Q. Chen; critical review of manuscript: all authors.</p>
    </sec>
    <sec sec-type="COI-statement" id="acn350798-sec-0018">
      <title>Conflict of Interest</title>
      <p>None of the authors have potential conflict of interest to be disclosed.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data" id="acn350798-sup-0001">
        <caption>
          <p>
<bold>Data S1</bold>
<bold>.</bold> Acquisition and initial image preprocessing of resting‐state fMRI data.</p>
        </caption>
        <media xlink:href="ACN3-6-1202-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="acn350798-sec-0016">
      <title>Acknowledgments</title>
      <p>This work was supported by grants from National Natural Science Foundation of China (81500905, 81201007) and Doctoral Fund of the Ministry of Education of China (20120101120070). We thank our patients and family members for their continuous effort and contribution to our clinical research.</p>
    </ack>
    <ref-list content-type="cited-references" id="acn350798-bibl-0001">
      <title>References</title>
      <ref id="acn350798-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0001">
<string-name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gleichman</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>EG</given-names>
</string-name>, et al. <article-title>Anti‐NMDA‐receptor encephalitis: case series and analysis of the effects of antibodies</article-title>. <source xml:lang="en">Lancet Neurol</source>
<year>2008</year>;<volume>7</volume>:<fpage>1091</fpage>–<lpage>1098</lpage>.<pub-id pub-id-type="pmid">18851928</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0002">
<string-name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lancaster</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Martinez‐Hernandez</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Clinical experience and laboratory investigations in patients with anti‐NMDAR encephalitis</article-title>. <source xml:lang="en">Lancet Neurol</source>
<year>2011</year>;<volume>10</volume>:<fpage>63</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">21163445</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0003">
<string-name>
<surname>Irani</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Bera</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Waters</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>N‐methyl‐D‐aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non‐paraneoplastic disorder of both sexes</article-title>. <source xml:lang="en">Brain</source>
<year>2010</year>;<volume>133</volume>(<issue>Pt 6</issue>):<fpage>1655</fpage>–<lpage>1667</lpage>.<pub-id pub-id-type="pmid">20511282</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0004">
<string-name>
<surname>Viaccoz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Desestret</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ducray</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis</article-title>. <source xml:lang="en">Neurology</source>
<year>2014</year>;<volume>82</volume>:<fpage>556</fpage>–<lpage>563</lpage>.<pub-id pub-id-type="pmid">24443452</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0005">
<string-name>
<surname>Florance</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents</article-title>. <source xml:lang="en">Ann Neurol</source>
<year>2009</year>;<volume>66</volume>:<fpage>11</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">19670433</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0006">
<string-name>
<surname>Titulaer</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>McCracken</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gabilondo</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Treatment and prognostic factors for long‐term outcome in patients with anti‐NMDA receptor encephalitis: an observational cohort study</article-title>. <source xml:lang="en">Lancet Neurol</source>
<year>2013</year>;<volume>12</volume>:<fpage>157</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">23290630</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0007">
<string-name>
<surname>McKeon</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>AE</given-names>
</string-name>, et al. <article-title>Cognitive outcomes following anti‐N‐methyl‐D‐aspartate receptor encephalitis: a systematic review</article-title>. <source xml:lang="en">J Clin Exp Neuropsychol</source>
<year>2018</year>;<volume>40</volume>:<fpage>234</fpage>–<lpage>252</lpage>.<pub-id pub-id-type="pmid">28585453</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0008">
<string-name>
<surname>Finke</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>UA</given-names>
</string-name>, <string-name>
<surname>Pruss</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Cognitive deficits following anti‐NMDA receptor encephalitis</article-title>. <source xml:lang="en">J Neurol Neurosurg Psychiatry</source>
<year>2012</year>;<volume>83</volume>:<fpage>195</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">21933952</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0009">
<string-name>
<surname>Keller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Roitman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ben‐Hur</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Anti‐NMDA receptor encephalitis presenting as an acute psychotic episode in a young woman: an underdiagnosed yet treatable disorder</article-title>. <source xml:lang="en">Case Rep Psychiatry</source>
<year>2014</year>;<volume>2014</volume>:<fpage>868325</fpage>.<pub-id pub-id-type="pmid">25400967</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0010">
<string-name>
<surname>Graus</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Titulaer</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Balu</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>A clinical approach to diagnosis of autoimmune encephalitis</article-title>. <source xml:lang="en">Lancet Neurol</source>
<year>2016</year>;<volume>15</volume>:<fpage>391</fpage>–<lpage>404</lpage>.<pub-id pub-id-type="pmid">26906964</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0011">
<string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Fouche</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Multivariate classification of social anxiety disorder using whole brain functional connectivity</article-title>. <source xml:lang="en">Brain Structure and Function</source>
<year>2015</year>;<volume>220</volume>:<fpage>101</fpage>–<lpage>115</lpage>.<pub-id pub-id-type="pmid">24072164</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0012">
<string-name>
<surname>Finke</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>UA</given-names>
</string-name>, <string-name>
<surname>Scheel</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Functional and structural brain changes in anti‐N‐methyl‐D‐aspartate receptor encephalitis</article-title>. <source xml:lang="en">Ann Neurol</source>
<year>2013</year>;<volume>74</volume>:<fpage>284</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">23686722</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0013">
<string-name>
<surname>Peer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pruss</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ben‐Dayan</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Functional connectivity of large‐scale brain networks in patients with anti‐NMDA receptor encephalitis: an observational study</article-title>. <source xml:lang="en">Lancet Psychiatry.</source>
<year>2017</year>;<volume>4</volume>:<fpage>768</fpage>–<lpage>774</lpage>.<pub-id pub-id-type="pmid">28882707</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0014">
<string-name>
<surname>Finke</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>UA</given-names>
</string-name>, <string-name>
<surname>Pajkert</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Structural hippocampal damage following anti‐N‐methyl‐D‐aspartate receptor encephalitis</article-title>. <source xml:lang="en">Biol Psychiat</source>
<year>2016</year>;<volume>79</volume>:<fpage>727</fpage>–<lpage>734</lpage>.<pub-id pub-id-type="pmid">25866294</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0015">
<string-name>
<surname>Wagner</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Kahn</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Buckner</surname>
<given-names>RL</given-names>
</string-name>. <article-title>Parietal lobe contributions to episodic memory retrieval</article-title>. <source xml:lang="en">Trends in cognitive sciences.</source>
<year>2005</year>;<volume>9</volume>:<fpage>445</fpage>–<lpage>453</lpage>.<pub-id pub-id-type="pmid">16054861</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0016">
<string-name>
<surname>Greicius</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Srivastava</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Reiss</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Menon</surname>
<given-names>V</given-names>
</string-name>. <article-title>Default‐mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>
<year>2004</year>;<volume>101</volume>:<fpage>4637</fpage>–<lpage>4642</lpage>.<pub-id pub-id-type="pmid">15070770</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0017">
<string-name>
<surname>Anderson</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Bunce</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Barbas</surname>
<given-names>H</given-names>
</string-name>. <article-title>Prefrontal–hippocampal pathways underlying inhibitory control over memory</article-title>. <source xml:lang="en">Neurobiol Learn Memory</source>
<year>2016</year>;<volume>134</volume>:<fpage>145</fpage>–<lpage>161</lpage>.</mixed-citation>
      </ref>
      <ref id="acn350798-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0018">
<string-name>
<surname>Albers</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Gilmore</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Kaye</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>At the interface of sensory and motor dysfunctions and Alzheimer's disease</article-title>. <source xml:lang="en">Alzheimers Dement</source>
<year>2015</year>;<volume>11</volume>:<fpage>70</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">25022540</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0019">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Apolipoprotein E epsilon4 modulates functional brain connectome in Alzheimer's disease</article-title>. <source xml:lang="en">Hum Brain Mapp</source>
<year>2015</year>;<volume>36</volume>:<fpage>1828</fpage>–<lpage>1846</lpage>.<pub-id pub-id-type="pmid">25619771</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0020">
<string-name>
<surname>Agosta</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rocca</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Pagani</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease</article-title>. <source xml:lang="en">Hum Brain Mapp</source>
<year>2010</year>;<volume>31</volume>:<fpage>515</fpage>–<lpage>525</lpage>.<pub-id pub-id-type="pmid">19777557</pub-id></mixed-citation>
      </ref>
      <ref id="acn350798-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="acn350798-cit-0021">
<string-name>
<surname>Fox</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Snyder</surname>
<given-names>AZ</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</string-name>, et al. <article-title>The human brain is intrinsically organized into dynamic, anticorrelated functional networks</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>
<year>2005</year>;<volume>102</volume>:<fpage>9673</fpage>–<lpage>9678</lpage>.<pub-id pub-id-type="pmid">15976020</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
